Patents Examined by Rei Tsang Shiao
-
Patent number: 11602532Abstract: Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage.Type: GrantFiled: January 2, 2019Date of Patent: March 14, 2023Assignee: CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.Inventors: Hongxing Wang, Shuanghong Liang, Yinzhou Fan, Zhenping Huang, Siting Zhao, Li Qin, Xiaoping Chen
-
Patent number: 11596615Abstract: Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R1-R14, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.Type: GrantFiled: July 17, 2020Date of Patent: March 7, 2023Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Salim Merali, Carlos A. Barrero, Wayne E. Childers, George C. Morton
-
Patent number: 11596638Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures.Type: GrantFiled: October 1, 2020Date of Patent: March 7, 2023Assignee: Mind Medicine, IncInventors: Scott Freeman, Stots B. Reele, Jeanne Bonelle
-
Patent number: 11596621Abstract: The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.Type: GrantFiled: March 23, 2020Date of Patent: March 7, 2023Assignee: ANNOVIS BIO, INC.Inventor: Maria Maccecchini
-
Patent number: 11590119Abstract: The present specification relates to (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid (AZD4017), or a pharmaceutically acceptable salt thereof, for oral use in the treatment or prophylaxis of wounds, for example in diabetic patients. Methods of treatment and prophylaxis and the use of the compound in the preparation of a medicament for the treatment and prophylaxis of wounds are also provided.Type: GrantFiled: November 11, 2020Date of Patent: February 28, 2023Assignee: University of LeedsInventors: Ana Tiganescu, Paul Stewart
-
Patent number: 11590167Abstract: The present disclosure relates to methods, compositions and uses involving immunotherapies and inhibitors of a target protein tyrosine kinase in which the kinase is not IL-2-inducible T cell kinase (ITK) and/or is selected from Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC), BMX non-receptor tyrosine kinase (Etk), TXK tyrosine kinase (TXK) and/or receptor tyro-sine-protein kinase ErbB4 (ErbB4). The provided methods, compositions and uses include administration of one or more such inhibitor with another agent, such as an immunotherapeutic agent targeting T cells and/or genetically engineered T cells, such as CAR-expressing T cells. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration, nucleic acids, articles of manufacture and kits.Type: GrantFiled: December 1, 2017Date of Patent: February 28, 2023Assignees: Juno Therapeutic, Inc., ACERTA PHARMA B.V.Inventors: Michael Ports, Jim Qin, Ruth Salmon, Oleksandr Baturevych
-
Patent number: 11584709Abstract: The invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns therapy for obesity, psoriasis, Crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting, as well as a number of other diseases associated with the activity of cathepsin S, cannabinoid receptors type 1, tachykinin receptors type 1 and 2, prokineticin receptors type 1 and 2, bradykinin receptors type 1, melanocortin receptors MC4R, serotonin receptors 5-HT2B and NB-kB signaling pathway, by using benzyl (2S)-2-[2-(4-hydroxyphenyl)acetamido]-3-phenylpropanoate compound. The compound and pharmaceutically acceptable adducts, hydrates and solvates thereof are a cathepsin S inhibitor, cannabinoid receptor type 1 agonist, tachykinin receptor type 1 and 2 antagonist, prokineticin receptor type 1 and 2 antagonist, bradykinin receptor type 1 antagonist, melanocortin receptor MC4R antagonist, serotonin receptor 5-HT2B antagonist, and NB-kB signaling pathway inhibitor.Type: GrantFiled: May 24, 2018Date of Patent: February 21, 2023Assignee: “PHARMENTERPRISES EURASIA” LIMITED LIABILITY COMPANYInventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova, Anastasia Vladimirovna Rydlovskaya
-
Patent number: 11576895Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.Type: GrantFiled: January 11, 2017Date of Patent: February 14, 2023Assignee: EPICENTRX, INCInventors: Bryan T. Oronsky, Jan Scicinski, Scott Caroen
-
Patent number: 11576920Abstract: A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of a wide range of common and rare pharmacological oils including specific formulations of jojoba oil, evening primrose oil, and borage seed oil. The solid phase bio-identical hormone component is comprised of either a standard coarse formulation or a formulation comprised of nanoparticles. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy.Type: GrantFiled: April 13, 2020Date of Patent: February 14, 2023Assignee: The Menopause Method, Inc.Inventors: Daved Rosensweet, Joshua B. Rosensweet
-
Patent number: 11571431Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.Type: GrantFiled: October 24, 2021Date of Patent: February 7, 2023Assignee: Galmed Research and Development LtdInventors: Allen Baharaff, Idit Eshkar-Oren
-
Patent number: 11571413Abstract: Described herein are methods of increasing meat quantity and/or improving meat quality of domesticated meat animals using treatments of nicotinamide riboside. The nicotinamide riboside may be in the form of a chloride salt mixed or dissolved in a biologically-acceptable carrier. The treatments may be provided as an in ovo injection or orally administered to the live domesticated meat animal. The methods described herein advantageously increase the size and weight of the domesticated meat animals, reduce the incidences of transportation fatigue, and decrease meat discoloration over time.Type: GrantFiled: June 26, 2020Date of Patent: February 7, 2023Assignee: Kansas State University Research FoundationInventors: John Michael Gonzalez, Stephanie Rene Kruger, Chad Bennett Paulk, Haley Kay Wecker, Kara Dunmire
-
Patent number: 11565998Abstract: The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.Type: GrantFiled: June 18, 2020Date of Patent: January 31, 2023Assignee: ABLIVA ABInventors: Magnus Joakim Hansson, Alvar Grönberg, Mats Eskil Elmér, Mark Richard Farmery, Steven James Moss, Lee Robert Webster, Matthew Alan Gregory
-
Patent number: 11566003Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: GrantFiled: July 6, 2020Date of Patent: January 31, 2023Assignee: Genentech, Inc.Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
-
Patent number: 11559528Abstract: Provided herein are compositions, systems, kits, and methods for treating a subject with cancer by administering a BACE1 inhibitor, such as MK-8931. In particular embodiments, the subject is treated with radiation (e.g., low dose radiation) first, and then administered a BACE1 inhibitor within a certain time window (e.g., about 3 hours to 6 days after the radiation treatment).Type: GrantFiled: September 3, 2020Date of Patent: January 24, 2023Assignee: The Cleveland Clinic FoundationInventors: Shideng Bao, Kui Zhai
-
Patent number: 11559498Abstract: A method of treating coronavirus infection, post-acute sequelae of coronavirus infection, and viral mediated respiratory distress in a subject in need thereof includes administering to the subject a therapeutically effective amount of agent that promotes, increases, and/or induces hemoglobin nitrosylation within red blood cells (RBCs) and GSNO levels in the lung or airways of the subject.Type: GrantFiled: December 27, 2021Date of Patent: January 24, 2023Assignee: UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTERInventor: Jonathan S. Stamler
-
Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
Patent number: 11547689Abstract: A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor where the composition is continuously administrated.Type: GrantFiled: March 22, 2019Date of Patent: January 10, 2023Assignee: Intrance International ABInventor: Roger Bolsöy -
Patent number: 11541066Abstract: The present invention provides stable ready-to-use parenteral compositions of fosaprepitant and its pharmaceutically acceptable salts or derivatives. The compositions of the present invention do not require reconstitution and/or dilution prior to administration to the patient, and are stable over the shelf-life of the product.Type: GrantFiled: March 3, 2022Date of Patent: January 3, 2023Assignee: EXTROVIS AGInventors: Krishna Mohan Chilakala, Hanumantha Rao Kamma, Janos Vaczi
-
Patent number: 11534428Abstract: The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered nifedipine in combination with a prostaglandin F2? (PGF2?) antagonist. Exemplary PGF2? receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride.Type: GrantFiled: May 14, 2019Date of Patent: December 27, 2022Assignee: XOMA (US) LLCInventors: Jean-Pierre Gotteland, Oliver Pohl
-
Patent number: 11534444Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.Type: GrantFiled: April 2, 2020Date of Patent: December 27, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Jean-Paul Pfefen, Heidemarie Kletzl, Lutz Mueller
-
Patent number: 11529363Abstract: Provided herein are methods for treating cancers (e.g., inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and neuroblastoma) in pediatric patients using brigatinib, as monotherapy or combination therapy with one or more second therapeutic agents.Type: GrantFiled: March 18, 2019Date of Patent: December 20, 2022Inventors: Sharon Bowen, Michael Hanley, David Kerstein, Karthik Venkatakrishnan